In summary, our findings demonstrate that the simultaneous suppression of the combination of the PI3K/mTOR inhibitor BEZ235 and the pan-HDAC inhibitor TSA is more effective than single agent in inhibiting the viability of breast cancer cells in vitro and tumour progression in vivo. This evidence concerns the gene HDAC9 and breast carcinoma.